128 completed, 43 unknown, 31 recruiting, 27 terminated. 92 Phase 2, 65 Phase 1, 43 Not applicable, 23 Phase 3, 10 Phase 4.
Follow Bile Duct Neoplasms: new trials by email Literature Review of Bile Duct Neoplasms trials Research Report on Bile Duct Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE) Music-assisted relaxation and imagery (MARI) - Surgery, Stomach Cancer | Not applicable | Not yet recruiting | Case Comprehensive Cancer Center | 20 | 2027-01-01 | 2026-08-05 |
| SumMET: Study of [225Ac]Ac-FL-261 in Participants With Solid Tumors Overexpressing c-MET [225Ac]Ac-FL-261 - Solid Tumor, NSCLC | Phase 1 / Phase 2 | Recruiting | Full-Life Technologies UK Limited | 208 | 2026-10-01 | 2026-10-16 |
| EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope Endoscopic ultrasound examination - Pancreatic Disease, Pancreatic Cancer | Not applicable | Recruiting | Orlando Health, Inc. | 140 | 2026-10-01 | 2026-10-20 |
| Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study FGFR Inhibitor, IDH1 mutation inhibitor, KRAS mutation inhibitor - Bile Duct Carcinoma, Cholangiocarcinoma | Phase 2 | Not yet recruiting | Zhejiang University | 240 | 2026-08-10 | 2026-07-28 |
| Suprapapillary Metal Stent vs. Routine Transpapillary Drainage in Malignant Hilar Biliary Obstruction (SMART-B Trial) Percutaneous transpapillary internal-external biliary drainage, Percutaneous suprapapillary biliary drainage with self-expanding metal stent - Cholangiocarcinoma, Bile Duct Neoplasms | Not applicable | Recruiting | Hospital de Clinicas de Porto Alegre | 84 | 2026-06-24 | 2026-10-01 |
| Safety of Biliary Intraductal Radiofrequency Ablation in Patients With Unresectable Extrahepatic Biliary Tract Cancer Gemcitabin, Cisplatin and Durvalumab, Biliary Radiofrequency Ablation, Endoscopic Retrograde Cholangio-Pancreatography with stenting - Bile Duct Cancer | Phase 2 | Recruiting | Insel Gruppe AG, University Hospital Bern | 36 | 2026-05-20 | 2026-05-26 |
| Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma (POELH-III) Registration of all findings during preoperative Endoscopic Ultrasound - Hilar Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma (Icc) | Recruiting | Erasmus Medical Center | 250 | 2026-02-05 | 2026-09-10 | |
| A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 BNT329, CA19-9-targeting monoclonal antibody - Advanced Solid Cancers | Phase 1 / Phase 2 | Recruiting | BioNTech SE | 245 | 2025-11-18 | 2026-10-15 |
| Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas Pancreaticojejunostomy with Modified N-Butyl-2-Cyanoacrylate (Glubran® 2), Standard(duct-to-mucosa) Pancreaticojejunostomy - Pancreatic Cancer, Periampullary Cancer | Not applicable | Recruiting | Minia University | 194 | 2025-09-15 | 2026-10-01 |
| Study of Large Channel Digital Pancreaticobiliary Scope (DPS) With Compatible Accessories Dragonfly™ Digital Pancreaticobiliary System - Bile Duct Adenocarcinoma, Bile Duct Carcinoma | Phase 4 | Recruiting | University of Colorado, Denver | 75 | 2025-08-11 | 2026-09-03 |
| Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma Stereotactic Body Radiotherapy (SBRT), Tislelizumab, Gemcitabine - Cholangiocarcinoma, Hilar Cholangiocarcinoma | Phase 2 | Recruiting | Jinbo Yue | 38 | 2025-07-01 | 2026-10-15 |
| A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors KJ015 Injection (Subcutaneous Injection) - Gastric/Gastroesophageal Junction Cancer, Breast Cancer | Phase 1 | Not yet recruiting | Shanghai Bao Pharmaceuticals Co., Ltd. | 66 | 2025-06-24 | 2025-06-25 |
| Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer PD-1/CTLA-4 Dual Functional Antibody, Gemcitabine, Cisplatin, Anlotinib - Bile Duct Carcinoma, Gall Bladder Cancer | Phase 2 | Recruiting | First Affiliated Hospital of Zhejiang University | 60 | 2025-06-01 | 2025-06-17 |
| On-treatment Surveillance of Tumor Evolution and Response to Systemic Treatment in Bile Duct and Liver Cancer Hepatocellular Carcinoma (HCC), Cholangiocarcinoma | Recruiting | Region Skane | 150 | 2025-05-15 | 2026-08-03 | |
| Target-specific immunoPET Imaging of Digestive System Carcinoma [68Ga]Ga-DOTA-H2D3, [18F]F-RESCA-RB14, [68Ga]Ga-NOTA-T4 - Malignancy, Digestive Cancer | Not applicable | Recruiting | RenJi Hospital | 400 | 2024-12-04 | 2025-12-31 |
| Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors Utidelone Capsule 60mg/m2/d, Utidelone capsule 75mg/m2, Utidelone Capsule - Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer | Phase 2 | Not yet recruiting | Beijing Biostar Pharmaceuticals Co., Ltd. | 100 | 2024-12-01 | 2024-12-12 |
| The Future Management of Patients With Neoplasms of the Gastro-intestinal Tract Molecular analyses - Pancreatic Adenocarcinoma, Cholangiocarcinoma | Not applicable | Active not recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 300 | 2024-12-01 | 2025-08-26 |
| Endoscopic Radiofrequency Ablation for Unresectable Cholangiocarcinoma Intraductal biliary radiofrequency ablation - Cholangiocarcinoma, Klatskin Tumor | Not applicable | Recruiting | Universitätsklinikum Hamburg-Eppendorf | 130 | 2024-08-30 | 2026-09-09 |
| A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors ACTM-838 - Solid Tumor | Phase 1 | Terminated | Actym Therapeutics, Inc. | 10 | 2024-06-05 | 2025-10-15 |
| A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) oxaliplatin, capecitabine, Keytruda - Biliary Cancer, Bile Duct Cancer | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 60 | 2024-05-08 | 2026-10-16 |
Showing 20 of 257. Sign in to see all of them.
Pancreatic Neoplasms (115) · Gallbladder Neoplasms (105) · Cholangiocarcinoma (74) · Stomach Neoplasms (69) · Carcinoma, Hepatocellular (67) · Liver Neoplasms (52) · Colonic Neoplasms (50) · Esophageal Neoplasms (46) · Rectal Neoplasms (43) · Colorectal Neoplasms (35) · Neoplasms (34) · Breast Neoplasms (32) · Carcinoma, Non-Small-Cell Lung (28) · Anus Neoplasms (26)
Digestive System Diseases (257) · Neoplasms by Site (257) · Biliary Tract Diseases (255) · Digestive System Neoplasms (255) · Bile Duct Diseases (251) · Biliary Tract Neoplasms (232) · Neoplasms (223) · Neoplasms by Histologic Type (156) · Neoplasms, Glandular and Epithelial (151) · Carcinoma (143) · Adenocarcinoma (137) · Endocrine Gland Neoplasms (123) · Endocrine System Diseases (123) · Pancreatic Diseases (113) · Gallbladder Diseases (106)
Gemcitabine (40) · Cisplatin (24) · Capecitabine (21) · Fluorouracil (19) · Oxaliplatin (17) · Leucovorin (14) · pembrolizumab (9) · Irinotecan (8) · Erlotinib Hydrochloride (7) · Radiotherapy (7) · durvalumab (6) · Carboplatin (4) · Dexamethasone (4) · Magnetic Resonance Spectroscopy (4) · Photochemotherapy (4)
National Cancer Institute (NCI) (27) · Memorial Sloan Kettering Cancer Center (7) · Mayo Clinic (5) · Seoul National University Hospital (5) · Alliance for Clinical Trials in Oncology (4) · National Institutes of Health Clinical Center (CC) (4) · Weill Medical College of Cornell University (4) · Ajou University School of Medicine (3) · Case Comprehensive Cancer Center (3) · Chiba University (3) · City of Hope Medical Center (3) · Merck Sharp & Dohme LLC (3) · RenJi Hospital (3) · Wakayama Medical University (3) · ASLAN Pharmaceuticals (2)
United States (145) · China (24) · South Korea (24) · Germany (19) · France (16) · Canada (14) · Australia (13) · United Kingdom (12) · Japan (11) · Spain (10) · Belgium (9) · Italy (8) · Sweden (7) · Taiwan (7) · Brazil (5)
Michel Kahaleh, MD (6) · Tim F Greten, M.D. (4) · Jonathan M Hernandez, M.D. (3) · Katsunori Furukawa, MD (3) · Tanios Bekaii-Saab (3) · Afshin Dowlati, MD (2) · Anthony El-Khoueiry (2) · Eva Szabo, MD (2) · Franco M. Muggia, MD (2) · Hedy Kindler (2) · Masaji Tani, MD (2) · Steven R. Alberts, MD (2) · Ahmed Kaseb (1)
PMID 29954008, PMID 32707155, PMID 34508767, PMID 38661512, PMID 42176183, PMID 12196376, PMID 12393999, PMID 15558814, PMID 15646530, PMID 16849762, PMID 17707751, PMID 18470481, PMID 18669454, PMID 18669455, PMID 19023677, PMID 19399502, PMID 19737952, PMID 20068553, PMID 20074698, PMID 20179219, PMID 20375404, PMID 21034892, PMID 21248633, PMID 21519026, PMID 21556747, PMID 22480131, PMID 23006802, PMID 24512954, PMID 24589090, PMID 24975853, PMID 25033929, PMID 25241229, PMID 25952086, PMID 25964250, PMID 26646758, PMID 26850262, PMID 26965712, PMID 27004243, PMID 27020837, PMID 27059973, PMID 27237786, PMID 27328985, PMID 27460387, PMID 28040257, PMID 28097515, PMID 28192597, PMID 29149611, PMID 29342492, PMID 29362244, PMID 30178032
P30CA015083 (4), U10CA032102 (4), 2015 (3), 2023 (3), N01CM62201 (3), N01CM00070 (2), N01CM17104 (2), N01CM62207 (2), P30CA013330 (2), P30CA016087 (2), P30CA033572 (2), P30CA043703 (2), P30CA068485 (2), U10CA180888 (2), 2016 (1)